Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Sintilimab + Radiotherapy vs Regorafenib in Advanced GIST After ≥2 TKIs
ChiCTR2600126996Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Regorafenib + Sintilimab + Radiotherapy (TIR combination) with Regorafenib Monotherapy (2 arms). Primary endpoint: progression-free survival (PFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
regorafenibsintilimab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR2600126996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126996.